Chinese medicinal material price index up 0.04%
The Kangmei Chinese medicinal material price index, a barometer of the traditional Chinese medicine (TCM) material market, rose 0.04 percent to 1,289.98 points Tuesday.
Covering more than 500 TCM materials including herbs and minerals from six major markets nationwide, the closely-watched index reflects the overall price trend in the country's TCM material market. It is released daily by Kangmei Pharmaceutical Co Ltd, one of China's major TCM companies.
The index was approved by the National Development and Reform Commission of China in 2012 to offer a more timely and accurate reference for TCM material growers, traders, and pharmaceutical companies.
Traditional Chinese medicines, often given as oral liquid, granule, and pills, typically use the combination of a number of medicinal materials, mostly herbs, to address health problems.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-07-16
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
Moderna to Cut 10 Percent of Staff as COVID Vaccine Sales Plunge Stock Drops 4 Percent
-
Smog Becomes a Sales Catalyst as Respiratory Drugs Surge in November
-
The FDA Officially Blesses AI for Liver Drug Development
-
Zydus Brings the First Keytruda Biosimilar Showdown to North America
-
U.S. FDA Opens New Safety Review of RSV Treatments for Infants
-
Lilly’s Mounjaro Enters China’s State Insurance System
-
Vertex Pushes Gene Therapy Into Younger Children With Blood Disorders
-
Wegovy Slips on Price While Mounjaro Defends Its Weight-Loss Crown
-
A New Obesity Pill Enters the Arena With Double-Digit Weight Loss
Recommend Reading
-
After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition
-
Betting on Next-Generation Metabolic Therapies: Pfizer’s Big Wager on Metsera and Its Strategic Reshaping in China
-
Small Pharma Firms Under Threat as Regulator Tightens Quality Norms
-
Merck Nears Acquisition of Cidara to Strengthen Flu Prevention Arsenal
-
Biocon Weighs Merger of Biocon Biologics to Unlock Value
-
Bolivia Uncovers 23 New Egg Smuggling Routes Weekly Contraband Soars to 12 Million Eggs
-
Arachidic Acid Uses: Food, Industrial Applications & Safety
-
Bayer Files Icafolin Herbicide in Four Major Markets Sales Forecast to Hit 750 Million Euros
-
Falling Crude Oil Prices Weigh Down Commodities; Maleic Anhydride Market Trends Also Weaken Accordingly
-
Recent Soda Ash Market Trend in China is Weak and Consolidating